LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Novel Method Developed for More Effective Noninvasive Prostate Cancer Screening

By LabMedica International staff writers
Posted on 16 Sep 2014
Image: Researchers have demonstrated potential for a new, noninvasive method to screen for prostate cancer using a detection system that combines surface-enhanced Raman scattering (SERS) with support vector machine (SVM) techniques (Photo courtesy of Prof. S. Li and Guangdong Medical College).
Image: Researchers have demonstrated potential for a new, noninvasive method to screen for prostate cancer using a detection system that combines surface-enhanced Raman scattering (SERS) with support vector machine (SVM) techniques (Photo courtesy of Prof. S. Li and Guangdong Medical College).
Comparing healthy volunteers and prostate cancer (PrCa) patients, researchers have successfully shown that their new method, which builds on the use of SERS spectroscopy of silver nanoparticles mixed with blood samples, could reveal cases of cancer.

A team of researchers led by Prof. Shaoxin Li, of Guangdong Medical College (Guangdong province, China), has demonstrated potential of a new noninvasive method to screen for PrCa based on combining of the existing technique of serum surface-enhanced Raman scattering (SERS) with the new sophisticated analysis technique called support vector machine (SVM). Applying the combined SERS-SVM system to blood samples collected from 68 healthy volunteers and 93 people clinically confirmed to have PrCa, their technique identified the PrCa cases with 98.1% accuracy.

If the technique proves safe and effective in clinical trials, it may become an effective method available to patients and their doctors for improving early diagnosis of PrCa. “The results demonstrate that label-free serum SERS analysis combined with SVM diagnostic algorithm has great potential,” said Prof. Li, “Compared to traditional screening methods, this method has the advantages of being noninvasive, highly sensitive, and very simple.”

The blood test for elevated levels of PSA (prostate specific antigen) commonly used for PrCa screening and monitoring is far from perfect as elevated PSA levels can be caused by many factors unrelated to cancer. This contributes to over-diagnosis, uncomfortable tissue biopsies, and other unnecessary treatment, which can be costly and carry significant side-effects. Because of this, the US Preventative Services Task Force now recommends against PSA-based screening for PrCa.

Other scientists have considered applying SERS to cancer detection as it would seem to enable detection of the subtle marker signals. The challenge, said Prof. Li, was that the signal differences between the serum samples taken from the healthy volunteers and the PrCa patients were too subtle to detect. So his team employed also the powerful spectral data processing algorithm SVM – and found it to be effective. While the work is preliminary, it demonstrates that the method has good potential for PrCa screening. The next research step, added Prof. Li, is to refine the method and explore whether it can distinguish cancer staging.

The method, described by S. Li et al, was published in the journal Applied Physical Letters, September 2, 2014, online.

Related Links:

Guangdong Medical College


Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
8-Channel Pipette
SAPPHIRE 20–300 µL
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more